Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fred Saad

Showing results (351-360 of 1,126) with videos related to

Pageof 113
Sort By:
Journal of the National Cancer Institute|January 6, 2005
Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumorsJanet E Brown, Richard J Cook, Pierre Major, et al.
European Urology|April 22, 2006
High radical prostatectomy surgical volume is related to lower radical prostatectomy total hospital chargesAlvaro Ramirez, Serge Benayoun, Alberto Briganti, et al.
European Journal of Cancer (Oxford, England : 1990)|April 2, 2013
Large-scale independent validation of the nuclear factor-kappa B p65 prognostic biomarker in prostate cancerPhilippe O Gannon, Laurent Lessard, Louis-Mathieu Stevens, et al.
Clinical Genitourinary Cancer|July 18, 2019
Disease Characteristics and Completion of Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer Treated With Radium-223 in an International Early Access ProgramFred Saad, Silke Gillessen, Daniel Heinrich, et al.
Urologic Oncology|July 13, 2019
How cancer-specific mortality changes over time after radical cystectomy: Conditional survival of patients with nonmetastatic urothelial carcinoma of the urinary bladderCarlotta Palumbo, Francesco A Mistretta, Sophie Knipper, et al.
The Journal of Urology|September 21, 2021
Clinical Outcomes and Adverse Events after First-Line Treatment in Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-AnalysisLuigi Nocera, Pierre I Karakiewicz, Mike Wenzel, et al.
Prostate Cancer and Prostatic Diseases|May 15, 2020
Concurrent or layered treatment with radium-223 and enzalutamide or abiraterone/prednisone: real-world clinical outcomes in patients with metastatic castration-resistant prostate cancerNeal Shore, Celestia S Higano, Daniel J George, et al.
Clinical Genitourinary Cancer|May 14, 2019
Contemporary Comparison of Clinicopathologic Characteristics and Survival Outcomes of Prostate Ductal Carcinoma and Acinar Adenocarcinoma: A Population-Based StudySophie Knipper, Felix Preisser, Elio Mazzone, et al.
Prostate Cancer and Prostatic Diseases|February 13, 2022
Exercise in advanced prostate cancer elevates myokine levels and suppresses in-vitro cell growthJin-Soo Kim, Dennis R Taaffe, Daniel A Galvão, et al.
The New England Journal of Medicine|June 28, 2018
Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate CancerMaha Hussain, Karim Fizazi, Fred Saad, et al.
Pageof 113

Showing results (351-360 of 1,126) with videos related to

Sort By:
Pageof 113
Journal of the National Cancer Institute|January 6, 2005
Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumorsJanet E Brown, Richard J Cook, Pierre Major, et al.
European Urology|April 22, 2006
High radical prostatectomy surgical volume is related to lower radical prostatectomy total hospital chargesAlvaro Ramirez, Serge Benayoun, Alberto Briganti, et al.
European Journal of Cancer (Oxford, England : 1990)|April 2, 2013
Large-scale independent validation of the nuclear factor-kappa B p65 prognostic biomarker in prostate cancerPhilippe O Gannon, Laurent Lessard, Louis-Mathieu Stevens, et al.
Clinical Genitourinary Cancer|July 18, 2019
Disease Characteristics and Completion of Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer Treated With Radium-223 in an International Early Access ProgramFred Saad, Silke Gillessen, Daniel Heinrich, et al.
Urologic Oncology|July 13, 2019
How cancer-specific mortality changes over time after radical cystectomy: Conditional survival of patients with nonmetastatic urothelial carcinoma of the urinary bladderCarlotta Palumbo, Francesco A Mistretta, Sophie Knipper, et al.
The Journal of Urology|September 21, 2021
Clinical Outcomes and Adverse Events after First-Line Treatment in Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-AnalysisLuigi Nocera, Pierre I Karakiewicz, Mike Wenzel, et al.
Prostate Cancer and Prostatic Diseases|May 15, 2020
Concurrent or layered treatment with radium-223 and enzalutamide or abiraterone/prednisone: real-world clinical outcomes in patients with metastatic castration-resistant prostate cancerNeal Shore, Celestia S Higano, Daniel J George, et al.
Clinical Genitourinary Cancer|May 14, 2019
Contemporary Comparison of Clinicopathologic Characteristics and Survival Outcomes of Prostate Ductal Carcinoma and Acinar Adenocarcinoma: A Population-Based StudySophie Knipper, Felix Preisser, Elio Mazzone, et al.
Prostate Cancer and Prostatic Diseases|February 13, 2022
Exercise in advanced prostate cancer elevates myokine levels and suppresses in-vitro cell growthJin-Soo Kim, Dennis R Taaffe, Daniel A Galvão, et al.
The New England Journal of Medicine|June 28, 2018
Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate CancerMaha Hussain, Karim Fizazi, Fred Saad, et al.
Pageof 113